01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Patients and tumor samples
Cell lines and cell culture
Reagents
Cell treatment and Western-blotting
Xenograft models and treatment protocol
Immunohistochemistry (IHC)
Fluorescence in situ hybridization (FISH)
Statistical analysis
Results and discussion
Results
Patient characteristics and establishment of PDX models
Characteristics
|
No. of patients (%)
|
Success rate(≥3 generation)
|
a
P value
|
---|---|---|---|
Gender
|
0.655
|
||
Male
|
24(75.0%)
|
6(25%)
|
|
Female
|
8(25.0%)
|
3(37.5%)
|
|
Age (years)
|
0.427
|
||
≥60
|
19(59.4%)
|
4(26.3%)
|
|
<60
|
13(40.6%)
|
5(30.7%)
|
|
Stage
|
0.648
|
||
I/II
|
6(18.8%)
|
1(16.7%)
|
|
III/IV
|
26(81.2%)
|
8(30.8%)
|
|
Differentiation
|
0.531
|
||
Moderate
|
8(25.0%)
|
2(25.0%)
|
|
Moderate-poor
|
9(28.1%)
|
4(44.4%)
|
|
Poor and undiff
|
15(46.9%)
|
3(20%)
|
|
Lauren classification
|
0.657
|
||
Intestinal
|
16(50.0%)
|
5(31.3%)
|
|
Diffuse
|
11(34.4%)
|
2(18.1%)
|
|
Mixed
|
5(15.6%)
|
2(40%)
|
|
Pre-surgery chemotherapy
|
0.382
|
||
yes
|
9(28.1%)
|
1(11.1%)
|
|
no
|
23(71.9%)
|
8(34.8%)
|
Her2, cMet and FGFR2 status in PDX models and GC patient cohort
Samples
|
HER2
|
cMet
|
FGFR2
|
|||||
---|---|---|---|---|---|---|---|---|
OP(%)
|
AP(%)
|
Positive(%)
|
OP(%)
|
AP(%)
|
AP(%)
|
|||
IHC3+
|
FISH
|
IHC /FISH
|
IHC3+
|
IHC2+
|
IHC3+/2+
|
FISH
|
FISH
|
|
A cohort of GC patients (
n = 163)
|
12(7.3%)
|
5(3.1%)
|
17(10.4%)
|
7(4.3%)
|
25(15.3%)
|
32(19.6%)
|
7(4.3%)
|
6(3.7%)
|
Corresponding patients of PDX models (
n = 32)
|
3(9.4%)
|
1(3.1%)
|
4(12.5%)
|
3(9.4%)
|
5(15.6%)
|
8(25.0%)
|
3(9.4%)
|
1(3.1%)
|
Patients
|
Patients/PDX models
|
|||||
---|---|---|---|---|---|---|
Models
|
Age
|
Stage
|
Lauren
|
Her2
|
cMet
|
FGFR2
|
G01
|
≥60
|
III
|
Mixed
|
-/-
|
-/-
|
-/-
|
G03
|
≥60
|
III
|
Mixed
|
-/-
|
IHC(2+)/FISH(-)
|
FISH(+)
|
G05
|
<60
|
III
|
Intestinal
|
IHC(3+)/FISH(+)
|
-/-
|
-/-
|
G16
|
<60
|
III
|
Intestinal
|
-/-
|
-/-
|
-/-
|
G27
|
≥60
|
III
|
Diffuse
|
-/-
|
-/-
|
-/-
|
G29
|
<60
|
III
|
Intestinal
|
-/-
|
-/-
|
-/-
|
G30
|
<60
|
II
|
Intestinal
|
-/-
|
IHC(3+)/FISH(+)
|
-/-
|
G31
|
<60
|
III
|
Intestinal
|
-/-
|
IHC(2+)/FISH(+)
|
-/-
|
G32
|
≥60
|
III
|
Diffuse
|
-/-
|
-/-
|
-/-
|
G26
a
|
≥60
|
III
|
Intestinal
|
IHC(2+)/FISH(-)
|
-/-
|
-/-
|
G28
a
|
<60
|
III
|
Diffuse
|
-/-
|
-/-
|
-/-
|
G21
a
|
≥60
|
III
|
Intestinal
|
-/-
|
-/-
|
-/-
|
G22
b
|
<60
|
II
|
Intestinal
|
-/-
|
-/-
|
-/-
|
G23
b
|
≥60
|
III
|
Intestinal
|
-/-
|
IHC(3+/0)/FISH(+/-)
c
|
-/-
|